Literature DB >> 24809463

Clozapine safety, 40 years later.

Michele Raja, Silvia Raja1.   

Abstract

Clozapine is, and will remain in the coming years, an irreplaceable drug in psychiatry which has elective indication in treatment-resistant schizophrenia, suicide risk in schizophrenia spectrum disorders, aggressiveness or violence in psychiatric patients, psychosis in Parkinson's disease, prevention and treatment of tardive dyskinesia. Unfortunately, the drug is largely underused for many and serious side effects. Only a good knowledge of these side effects and of the main strategies to prevent their occurrence or minimize their impact can allow overcoming the underutilization of this valuable therapy. The article describes the clinical and epidemiological features of the non-motor side effects of clozapine including blood dyscrasias, constipation, diabetes, enuresis, fever, hepatitis, hypersalivation, ileus, myocarditis, nephritis, priapism, seizures, serositis, weight gain and metabolic syndrome. The paper suggests several strategies, supported by scientific evidence, in the management of these side effects. The neuropsychiatric side effects of clozapine are not discussed in this review.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24809463     DOI: 10.2174/1574886309666140428115040

Source DB:  PubMed          Journal:  Curr Drug Saf        ISSN: 1574-8863


  9 in total

Review 1.  Continuing clozapine treatment with lithium in schizophrenic patients with neutropenia or leukopenia: brief review of literature with case reports.

Authors:  Memduha Aydin; Bilge Cetin Ilhan; Saliha Calisir; Seda Yildirim; Ibrahim Eren
Journal:  Ther Adv Psychopharmacol       Date:  2016-02

Review 2.  Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine.

Authors:  Domenico De Berardis; Gabriella Rapini; Luigi Olivieri; Domenico Di Nicola; Carmine Tomasetti; Alessandro Valchera; Michele Fornaro; Fabio Di Fabio; Giampaolo Perna; Marco Di Nicola; Gianluca Serafini; Alessandro Carano; Maurizio Pompili; Federica Vellante; Laura Orsolini; Giovanni Martinotti; Massimo Di Giannantonio
Journal:  Ther Adv Drug Saf       Date:  2018-02-06

Review 3.  Delayed Initiation of Clozapine Continues to Be a Substantial Clinical Concern.

Authors:  Alexander Panickacheril John; Elvin Kay Fon Ko; Arun Dominic
Journal:  Can J Psychiatry       Date:  2018-04-22       Impact factor: 4.356

Review 4.  Prevalence and Predictors of Clozapine-Associated Constipation: A Systematic Review and Meta-Analysis.

Authors:  Ayala Shirazi; Brendon Stubbs; Lucia Gomez; Susan Moore; Fiona Gaughran; Robert J Flanagan; James H MacCabe; John Lally
Journal:  Int J Mol Sci       Date:  2016-06-02       Impact factor: 5.923

Review 5.  Treatment-resistant schizophrenia: current insights on the pharmacogenomics of antipsychotics.

Authors:  John Lally; Fiona Gaughran; Philip Timms; Sarah R Curran
Journal:  Pharmgenomics Pers Med       Date:  2016-11-07

6.  Authors' reply - Clozapine for mitochondrial psychosis.

Authors:  Caroline Demily; Charlyne Duwime; Alice Poisson; Nathalie Boddaert; Arnold Munnich
Journal:  Mol Genet Metab Rep       Date:  2017-02-06

7.  Chemistry-based molecular signature underlying the atypia of clozapine.

Authors:  T Cardozo; E Shmelkov; K Felsovalyi; J Swetnam; T Butler; D Malaspina; S V Shmelkov
Journal:  Transl Psychiatry       Date:  2017-02-21       Impact factor: 6.222

8.  Clozapine-induced myocarditis: Two case reports and review of clinical presentation and recognition.

Authors:  Bryan K Sackey; Troy A Moore; Nicole L Cupples; Cynthia A Gutierrez
Journal:  Ment Health Clin       Date:  2018-11-01

9.  The side effect profile of Clozapine in real world data of three large mental health hospitals.

Authors:  Ehtesham Iqbal; Risha Govind; Alvin Romero; Olubanke Dzahini; Matthew Broadbent; Robert Stewart; Tanya Smith; Chi-Hun Kim; Nomi Werbeloff; James H MacCabe; Richard J B Dobson; Zina M Ibrahim
Journal:  PLoS One       Date:  2020-12-08       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.